Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Compugen stock (CGEN)

Buy Compugen stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Compugen is a biotechnology business based in the US. Compugen shares (CGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.53 – a decrease of 4.97% over the previous week. Compugen employs 68 staff and has a trailing 12-month revenue of around $42.7 million.

Our top picks for where to buy Compugen stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy Compugen stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – CGEN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Compugen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Product USFST Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Finder score
Stocks, ETFs
$0
$0
N/A
Earn up to $300
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Compugen stock price (NASDAQ: CGEN)

Use our graph to track the performance of CGEN stocks over time.

Compugen shares at a glance

Information last updated 2024-12-19.
Latest market close$1.53
52-week range$1.35 - $3.03
50-day moving average $1.62
200-day moving average $1.93
Wall St. target price$4.00
PE ratio 50.3333
Dividend yield N/A
Earnings per share (TTM) $0.03

Is it a good time to buy Compugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Compugen price performance over time

Historical closes compared with the close of $1.52 from 2024-12-19

1 week (2024-12-13) -5.59%
1 month (2024-11-21) 4.83%
3 months (2024-09-20) -16.94%
6 months (2024-06-21) -22.84%
1 year (2023-12-21) -12.64%
2 years (2022-12-21) 85.39%
3 years (2021-12-21) 4.43
5 years (2019-12-20) 5.62

Is Compugen stock undervalued or overvalued?

Valuing Compugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Compugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Compugen's P/E ratio

Compugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Compugen shares trade at around 50x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Compugen financials

Revenue TTM $42.7 million
Gross profit TTM $6.5 million
Return on assets TTM -3.04%
Return on equity TTM -15.84%
Profit margin -22.31%
Book value $0.74
Market Capitalization $135.2 million

TTM: trailing 12 months

Compugen share dividends

We're not expecting Compugen to pay a dividend over the next 12 months.

Compugen share price volatility

Over the last 12 months, Compugen's shares have ranged in value from as little as $1.35 up to $3.0301. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.647. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Compugen overview

Compugen Ltd. , a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd.

Frequently asked questions

null
What percentage of Compugen is owned by insiders or institutions?
Currently 5.376% of Compugen shares are held by insiders and 14.967% by institutions.
How many people work for Compugen?
Latest data suggests 68 work at Compugen.
When does the fiscal year end for Compugen?
Compugen's fiscal year ends in December.
Where is Compugen based?
Compugen's address is: Azrieli Center, Holon, Israel, 5885849
What is Compugen's ISIN number?
Compugen's international securities identification number is: IL0010852080
What is Compugen's CUSIP number?
Compugen's Committee on Uniform Securities Identification Procedures number is: M25722105

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site